Skip to content
Markets News
Stocks1 min read

Zymeworks Licenses ZW209 to Roche With $55 Million Upfront

Makkler Newsroom
October 23, 2026 · Based on reporting by GlobeNewswire, finanzen.net

Zymeworks will receive $55 million upfront and may earn milestone payments and royalties as Roche takes global development rights to ZW209.

Key takeaways

  • Zymeworks is eligible for $55 million upfront and up to $718 million in additional milestone payments.
  • Roche will fund the Phase 1a trial and hold exclusive global development and commercialization rights.

Zymeworks has signed a global license and collaboration agreement with Roche for its cancer drug candidate ZW209, with $55 million due upfront and up to $718 million in additional milestone payments.

Zymeworks may also receive $40 million when a Phase 1b trial begins and tiered royalties on future net sales of any approved medicines. The agreement remains subject to the expiration or termination of a U.S. antitrust waiting period and other closing conditions.

Zymeworks will conduct the Phase 1a monotherapy trial with Roche funding it. Roche will handle subsequent global development and commercialization, pending the deal’s completion.

As of 15:52 UTC on Friday, Zymeworks shares traded at $28.04, down 1.41% from the previous close.

Topics
ZYMEROROG.SW
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.